PDMR Transaction Notification

Source: RNS
RNS Number : 3846J
Shield Therapeutics PLC
23 August 2021



Shield Therapeutics plc

("Shield Therapeutics" or the "Company")


PDMR Transaction Notification


London, UK, 23 August 2021: Shield Therapeutics plc (LSE:STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces that Mr Anders Lundstrom, Non-Executive Director, acquired 10,000 Ordinary Shares in the Company on 20 August 2021 at an average price of $0.61 per share. Following the transaction, Mr Lundstrom has a beneficial interest in 10,000 shares.


The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:



Details of the person discharging managerial responsibilities / person closely associated



Anders Lundstrom


Reason for the notification



Non-Executive Director


Initial notification




Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



Shield Therapeutics plc





Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted


Description of the

Financial instrument, type

of instrument

Identification code

Ordinary shares of 1.5p each in the capital of the Company




ISIN of Ordinary Shares: GB00BYV81293


Nature of the transaction


Acquisition of Ordinary Shares



Price(s) and volume(s)








Aggregated information

·      Aggregated volume

·      Price








Date of the transaction



Place of the transaction






For further information, please contact:


Shield Therapeutics plc

+44 (0) 191 511 8500

Greg Madison (CEO)

Hans-Peter Rudolf (CFO)

Peel Hunt LLP - Nominated Adviser & Joint Broker

                +44 (0) 20 7148 8900

James Steel / Christopher Golden

finnCap Ltd - Joint Broker

              +44 (0) 20 7220 0500

Geoff Nash / Alice Lane/ George Dollemore  



Walbrook PR - Financial PR & IR Adviser

+44 (0) 20 7933 8780

Paul McManus / Lianne Cawthorne/ Alice Woodings

or shield@walbrookpr.com



About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.


Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK, Switzerland and Australia and has exclusive IP rights until the mid-2030s. The Group is currently launching Accrufer® in the US. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. 


For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.